This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines. However, only a subset of ergolines are associated with fibrosis and evidence suggests that nicergoline does not carry the same fibrotic risk like other ergoline derivatives such as ergotamine.
This is based on an analysis of data showing a correlation between these medications and an increased risk of fibrosis and ergotism. However, only a subset of ergolines are linked to fibrosis, and research indicates that nicergoline does not carry the same level of fibrotic risk as other ergoline compounds such as ergotamine.